

Sebastian Palmqvist

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6829852/publications.pdf>

Version: 2024-02-01

137
papers

11,024
citations

38720

50
h-index

34964

98
g-index

154
all docs

154
docs citations

154
times ranked

8364
citing authors

#	ARTICLE	IF	CITATIONS
1	Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. <i>Alzheimer's and Dementia</i> , 2023, 19, 797-806.	0.4	24
2	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A β ₄₂ /A β ₄₀ and p-tau. <i>Alzheimer's and Dementia</i> , 2022, 18, 283-293.	0.4	72
3	Association of β -Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. <i>Neurology</i> , 2022, 98, .	1.5	22
4	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer's Disease Pathology and Cognitive Decline. <i>Biological Psychiatry</i> , 2022, 92, 34-43.	0.7	21
5	Components of gait in people with and without mild cognitive impairment. <i>Gait and Posture</i> , 2022, 93, 83-89.	0.6	7
6	The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders. <i>Movement Disorders</i> , 2022, 37, 993-1003.	2.2	8
7	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 149.	4.5	66
8	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 46.	3.0	17
9	Association of CSF A β ₃₈ Levels With Risk of Alzheimer Disease-Related Decline. <i>Neurology</i> , 2022, 98, .	1.5	16
10	Blood-based biomarkers for Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2022, 14, e14408.	3.3	122
11	Astrocytic function is associated with both amyloid- β and tau pathology in non-demented APOE ϵ ₄ carriers. <i>Brain Communications</i> , 2022, 4, .	1.5	4
12	Spatial Distribution of Tau and β -Amyloid Pathologies and Their Role in Different Alzheimer Disease Phenotypes. <i>Neurology</i> , 2021, 96, 191-192.	1.5	1
13	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 683-691.	1.7	8
14	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ϵ ₄ , sex and age. <i>Progress in Neurobiology</i> , 2021, 198, 101904.	2.8	25
15	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. <i>Nature Aging</i> , 2021, 1, 114-123.	5.3	94
16	Associations of Plasma Phospho-Tau ₂₁₇ Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 149.	4.5	176
17	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2245-2258.	3.3	27
18	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 76.	2.4	78

#	ARTICLE	IF	CITATIONS
19	Biomarker testing in MCI patientsâ€”deciding who to test. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 14.	3.0	6
20	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. <i>Brain</i> , 2021, 144, 2771-2783.	3.7	78
21	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new diseaseâ€”modifying treatmentsâ€”EQâ€”5D data from the Swedish BioFINDER study. <i>Alzheimer's and Dementia</i> , 2021, 17, 1832-1842.	0.4	5
22	Prediction of future Alzheimerâ€™s disease dementia using plasma phospho-tau combined with other accessible measures. <i>Nature Medicine</i> , 2021, 27, 1034-1042.	15.2	236
23	Soluble Pâ€”tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. <i>EMBO Molecular Medicine</i> , 2021, 13, e14022.	3.3	90
24	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. <i>Brain</i> , 2021, 144, 2826-2836.	3.7	65
25	Plasma biomarkers of Alzheimerâ€™s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. <i>Nature Communications</i> , 2021, 12, 3555.	5.8	115
26	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	5.8	219
27	Tau PET correlates with different Alzheimerâ€™s diseaseâ€”related features compared to CSF and plasma pâ€”tau biomarkers. <i>EMBO Molecular Medicine</i> , 2021, 13, e14398.	3.3	58
28	Plasma GFAP is an early marker of amyloid-Î² but not tau pathology in Alzheimerâ€™s disease. <i>Brain</i> , 2021, 144, 3505-3516.	3.7	198
29	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 961.	4.5	148
30	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. <i>Neurology</i> , 2021, 97, e1681-e1694.	1.5	60
31	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimerâ€™s disease. <i>Scientific Reports</i> , 2021, 11, 19853.	1.6	6
32	Connecting Cohorts to Diminish Alzheimerâ€™s Disease (CONCORD-AD): A Report of an International Research Collaboration Network. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-15.	1.2	1
33	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	6
34	Ability of tauâ€”PET, phosphoâ€”tau217, NfL and cortical thickness to predict shortâ€”term cognitive decline in early symptomatic Alzheimerâ€™s disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
35	Unravelling drivers of ageâ€”and betaâ€”amyloidâ€”related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
36	Biomarker driven enrichment strategies for tau pathology in AD clinical trials. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
37	Tau and synaptic biomarkers but not amyloid β are associated with cerebral perfusion in the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
38	Plasma glial fibrillary acidic protein is an early and specific marker of amyloid β pathology in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
39	Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
40	Lower cognitive resilience against brain atrophy in cognitively unimpaired elderly is partly explained by Alzheimer's disease pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
41	Comparing the clinical utility and diagnostic performance of cerebrospinal fluid τ 181, τ 217 and τ 231 assays. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
42	Amyloid β accumulation is independently related to executive function in cognitively unimpaired adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
43	Associations between cerebrospinal fluid markers of neuroinflammation and longitudinal measurements of white matter lesions. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
44	Associations between longitudinal neuropsychiatric symptoms and biomarkers of beta β amyloid, tau, neurodegeneration, and cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
45	The association between diet in mid-life and dementia incidence over a 20-year period. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
46	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
47	Potential drivers of age- and beta β amyloid-related neurodegeneration in early and late Alzheimer's Disease regions in cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
48	Prediction of future Alzheimer's disease dementia using plasma phospho τ combined with other accessible measures. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
49	Genetic interaction study of Alzheimer's disease quantitative biomarkers: A polygenic risk score analysis and evaluation.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e053556.	0.4	0
50	Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 335-344.	0.4	73
51	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3234-3241.	3.7	150
52	Derivation and utility of an β -PET pathology accumulation index to estimate β load. <i>Neurology</i> , 2020, 95, e2834-e2844.	1.5	14
53	Unburdening dementia – a basic social process grounded theory based on a primary care physician survey from 25 countries. <i>Scandinavian Journal of Primary Health Care</i> , 2020, 38, 253-264.	0.6	9
54	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 772.	3.8	640

#	ARTICLE	IF	CITATIONS
55	Coping Styles among People with Parkinson's Disease: A Three-Year Follow-Up Study. Behavioral Sciences (Basel, Switzerland), 2020, 10, 190.	1.0	5
56	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that are impacted by APOE ϵ 4, sex and age but not pathology. Alzheimer's and Dementia, 2020, 16, e040745.	0.4	0
57	Genome-wide polygenic risk scores for identification of gene therapeutic target. Alzheimer's and Dementia, 2020, 16, e040903.	0.4	0
58	Health utility in preclinical and prodromal AD compared to controls: EQ5D data from the Swedish Biofinder Study. Alzheimer's and Dementia, 2020, 16, e041032.	0.4	0
59	Biomarker testing in MCI patients: Deciding who to tap. Alzheimer's and Dementia, 2020, 16, e042735.	0.4	0
60	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nature Communications, 2020, 11, 6252.	5.8	36
61	Brief Cognitive Tests Used in Primary Care Cannot Accurately Differentiate Mild Cognitive Impairment from Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2020, 75, 1191-1201.	1.2	31
62	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurology, 2020, 77, 955.	4.5	136
63	The implications of different approaches to define AT(N) in Alzheimer disease. Neurology, 2020, 94, e2233-e2244.	1.5	80
64	Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up. NeuroImage: Clinical, 2020, 27, 102310.	1.4	10
65	Mild to Moderate Cognitive Impairment Does Not Affect the Ability to Self-Report Important Symptoms in Patients With Cancer: A Prospective Longitudinal Multinational Study (EPCCS). Journal of Pain and Symptom Management, 2020, 60, 346-354.e2.	0.6	4
66	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. Alzheimer's Research and Therapy, 2020, 12, 30.	3.0	14
67	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	4.5	80
68	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nature Medicine, 2020, 26, 379-386.	15.2	643
69	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nature Communications, 2020, 11, 1683.	5.8	252
70	A β 2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Science Advances, 2020, 6, eaaz2387.	4.7	202
71	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	4.9	668
72	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain, 2020, 143, 3805-3815.	3.7	65

#	ARTICLE	IF	CITATIONS
73	β^2 -amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. <i>Scientific Reports</i> , 2019, 9, 11180.	1.6	28
74	Determining clinically meaningful decline in preclinical Alzheimer disease. <i>Neurology</i> , 2019, 93, e322-e333.	1.5	96
75	Staging β^2 -Amyloid Pathology With Amyloid Positron Emission Tomography. <i>JAMA Neurology</i> , 2019, 76, 1319.	4.5	149
76	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2019, 11, e11170.	3.3	228
77	A quick test of cognitive speed can predict development of dementia in Parkinson's disease. <i>Scientific Reports</i> , 2019, 9, 15417.	1.6	11
78	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	4.9	85
79	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β^2 -Amyloid Status. <i>JAMA Neurology</i> , 2019, 76, 1060.	4.5	282
80	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. <i>Cerebral Cortex</i> , 2019, 29, 2173-2182.	1.6	39
81	Relating Experienced To Recalled breathlessness Observational (RETRO) study: a prospective study using a mobile phone application. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000370.	1.2	7
82	DTIC01: DIAGNOSTIC PERFORMANCE OF [¹⁸ F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDER ² STUDY. <i>Alzheimer's and Dementia</i> , 2019, 15, P1485.	0.4	0
83	Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 109.	3.0	14
84	Brain myoinositol as a potential marker of amyloid-related pathology. <i>Neurology</i> , 2019, 92, e395-e405.	1.5	30
85	Associations between tau, β^2 , and cortical thickness with cognition in Alzheimer disease. <i>Neurology</i> , 2019, 92, e601-e612.	1.5	196
86	Accurate risk estimation of β^2 -amyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. <i>Alzheimer's and Dementia</i> , 2019, 15, 194-204.	0.4	49
87	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. <i>ELife</i> , 2019, 8, .	2.8	57
88	Comparing [¹⁸ F] F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018, 90, e388-e395.	1.5	83
89	Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages. <i>Cerebral Cortex</i> , 2018, 28, 340-349.	1.6	28
90	Cerebral hypoperfusion is not associated with an increase in amyloid β^2 pathology in middle-aged or elderly people. <i>Alzheimer's and Dementia</i> , 2018, 14, 54-61.	0.4	21

#	ARTICLE	IF	CITATIONS
91	P3â€492: THE MISINTERPRETED AGE EFFECT ON COGNITIVE TEST RESULTS: A PRESENTATION OF TEST NORMS FROM PERSONS WITHOUT UNDERLYING PATHOLOGIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P1310.	0.4	0
92	P4â€078: CONCORDEâ€AD: AN INTERNATIONAL NETWORK OF COHORTS FOR BETTER UNDERSTANDING OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1465.	0.4	0
93	O3â€14â€05: ASSOCIATIONS OF CSF BIOMARKERS OF NEUROINFLAMMATION AND CEREBROVASCULAR DYSFUNCTION WITH ALZHEIMER'S DISEASE PATHOLOGY AND CLINICAL PROGRESSION. <i>Alzheimer's and Dementia</i> , 2018, 14, P1061.	0.4	0
94	DTâ€01â€06: COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE: A COMPARISON AND SYNTHESIS OF LARGE INTERNATIONAL COHORTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1667.	0.4	0
95	P1â€430: EFFECTS OF <i>APOE</i> ϵ 4 ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P473.	0.4	0
96	O2â€15â€04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P661.	0.4	0
97	F1â€04â€01: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€DEMENTED ELDERLY SUBJECTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P206.	0.4	0
98	P1â€373: τ 2-AMYLOID AND WHITE MATTER LESIONS ARE INDEPENDENTLY ASSOCIATED WITH HIPPOCAMPAL ATROPHY AND REDUCED CORTICAL TEMPORAL THICKNESS. <i>Alzheimer's and Dementia</i> , 2018, 14, P439.	0.4	0
99	O3â€04â€01: ASSOCIATIONS BETWEEN TAU, τ 2 AND CORTICAL THICKNESS WITH COGNITION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1018.	0.4	0
100	DTâ€02â€04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA τ 2 BIOMARKER ASSAYS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1670.	0.4	1
101	ICâ€Pâ€036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€DEMENTED ELDERLY SUBJECTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P39.	0.4	0
102	O2â€09â€01: CSF, PLASMA AND MRI BIOMARKER TRAJECTORIES DURING THE DEVELOPMENT OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P641.	0.4	0
103	Discriminative Accuracy of [¹⁸ F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1151.	3.8	298
104	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. <i>Neurology</i> , 2018, 91, e867-e877.	1.5	207
105	Effects of APOE ϵ 4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 71, 81-90.	1.5	15
106	Greater tau load and reduced cortical thickness in APOE ϵ 4-negative Alzheimer's disease: a cohort study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 77.	3.0	56
107	Earliest accumulation of τ 2-amyloid occurs within the default-mode network and concurrently affects brain connectivity. <i>Nature Communications</i> , 2017, 8, 1214.	5.8	596
108	¹⁸ F- <i>AVâ€1451</i> and CSF τ and <i>Pâ€tau</i> as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2017, 9, 1212-1223.	3.3	156

#	ARTICLE	IF	CITATIONS
109	[P3â€“284]: THE MONTREAL COGNITIVE ASSESSMENT: NORMATIVE DATA FROM A LARGE SWEDISH POPULATIONâ€“BASED COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1051.	0.4	0
110	[O2â€“01â€“02]: THE AMYLOID RISK SCORE: AN ACCURATE AND CROSSâ€“VALIDATED METHOD THAT PREDICTS CEREBRAL Î²â€“AMYLOIDOSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P548.	0.4	0
111	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimerâ€™s disease. <i>Brain</i> , 2017, 140, 2286-2294.	3.7	149
112	The Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-Based Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 893-901.	1.2	133
113	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and AÎ² Pathology in Non-demented Individuals. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 306.	1.7	30
114	Reply: Do we still need positron emission tomography for early Alzheimerâ€™s disease diagnosis?. <i>Brain</i> , 2016, 139, e61-e61.	3.7	5
115	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2016, 8, 1184-1196.	3.3	219
116	O2â€“08â€“06: CSF Analysis Detects Cerebral Bâ€“Amyloid Accumulation Earlier than Amyloid Pet. <i>Alzheimer's and Dementia</i> , 2016, 12, P246.	0.4	0
117	Cerebrospinal fluid analysis detects cerebral amyloid-Î² accumulation earlier than positron emission tomography. <i>Brain</i> , 2016, 139, 1226-1236.	3.7	292
118	Plasma tau in Alzheimer disease. <i>Neurology</i> , 2016, 87, 1827-1835.	1.5	371
119	Assessing risk for preclinical Î²â€“amyloid pathology with <i>APOE</i>, cognitive, and demographic information. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 76-84.	1.2	49
120	Plasma Î²-amyloid in Alzheimerâ€™s disease and vascular disease. <i>Scientific Reports</i> , 2016, 6, 26801.	1.6	442
121	Increased amyloidogenic APP processing in APOE É4-negative individuals with cerebral Î²-amyloidosis. <i>Nature Communications</i> , 2016, 7, 10918.	5.8	48
122	<sc>CSF</sc> A<i>Î²</i></i>42/A<i>Î²</i></i>40 and A<i>Î²</i></i>42/A<i>Î²</i></i>38 ratios: better diagnostic markers of Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 154-165.	1.7	329
123	O1â€“07â€“01: Diagnostic comparison of regional amyloid PET and different CSF biomarker assays for identifying early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, P140.	0.4	1
124	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. <i>Neurology</i> , 2015, 85, 1240-1249.	1.5	288
125	A Quick Test of Cognitive Speed: norm-referenced criteria for 121 Italian adults aged 45 to 90 years. <i>International Psychogeriatrics</i> , 2014, 26, 1493-1500.	0.6	8
126	P2-290: BIOMARKERS FOR IDENTIFYING NEURODEGENERATIVE DISORDERS EARLY AND RELIABLY (BIOFINDER): METHODOLOGY AND PRELIMINARY RESULTS OF A NEW LARGE PROSPECTIVE COHORT STUDY. , 2014, 10, P583-P584.		0

#	ARTICLE	IF	CITATIONS
127	Cerebral inflammation is an underlying mechanism of early death in Alzheimer's disease: a 13-year cause-specific multivariate mortality study. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 41.	3.0	33
128	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β -Amyloid 42. <i>JAMA Neurology</i> , 2014, 71, 1282.	4.5	300
129	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. <i>JAMA Psychiatry</i> , 2014, 71, 1183.	6.0	85
130	Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 113-122.	0.6	20
131	Dysphagia in Lewy body dementia - a clinical observational study of swallowing function by videofluoroscopic examination. <i>BMC Neurology</i> , 2013, 13, 140.	0.8	31
132	Gender-Dependent Levels of Hyaluronic Acid in Cerebrospinal Fluid of Patients with Neurodegenerative Dementia. <i>Current Alzheimer Research</i> , 2012, 9, 257-266.	0.7	17
133	Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study. <i>PLoS ONE</i> , 2012, 7, e38639.	1.1	73
134	Association between Subcortical Lesions and Behavioral and Psychological Symptoms in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 417-423.	0.7	33
135	A Quick Test of cognitive speed is sensitive in detecting early treatment response in alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2010, 2, 29.	3.0	29
136	Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests. <i>International Journal of Geriatric Psychiatry</i> , 2009, 24, 1405-1412.	1.3	72
137	The Usefulness of Cube Copying for Evaluating Treatment of Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2008, 23, 439-446.	0.9	11